Comments on: Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab

Comments on: Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab https://www.novumpr.nl/2017/10/23/biogen-and-eisai-expand-existing-collaboration-agreement-to-develop-and-commercialize-investigational-alzheimers-disease-treatments-including-phase-3-aducanumab/?utm_source=rss&utm_medium=rss&utm_campaign=biogen-and-eisai-expand-existing-collaboration-agreement-to-develop-and-commercialize-investigational-alzheimers-disease-treatments-including-phase-3-aducanumab NovumPR press releases Mon, 23 Oct 2017 15:13:13 +0000 hourly 1 https://wordpress.org/?v=6.8.3